Amgen posts higher 2Q sales, profit to beat views

July 27, 2012 by LINDA A. JOHNSON

(AP) — Amgen Inc.'s second-quarter net income rose 8 percent as the world's largest biotech company benefited from higher sales for its top-selling drugs and a gain from selling its share of an experimental medicine.

The results Thursday crushed Wall Street expectations, and shares jumped in after-hours trading. The company, based in Thousand Oaks, California, also raised its earnings and revenue forecasts for the year.

The maker of osteoporosis drug Prolia and Enbrel for inflammatory disorders said net income was $1.27 billion, or $1.61 per share, up from $1.17 billion, or $1.25 per share, a year earlier.

Amgen's adjusted results beat the expectations of analysts surveyed by FactSet by 29 cents per share, and revenue came in $400 million higher than expected.

Excluding one-time items, Amgen's second-quarter was $1.43 billion, or $1.83 per share, up from $1.28 billion, or $1.37 per share, in 2011's second quarter.

Revenue totaled $4.48 billion, up 13 percent from $3.96 billion a year ago.

Robert Bradway, who took over as Amgen's CEO in May, told analysts on a conference call that Amgen raised its financial forecast due to its strong performance in the first half and momentum from rising sales and promising drugs in development.

He noted Amgen has begun a second late-stage study of a new osteoporosis drug and is planning a late-stage study of a drug to treat a thyroid disorder in kidney disease patients getting dialysis. It's also starting a late-stage study of a cholesterol drug meant for patients who can't bring their bad cholesterol down enough with drugs currently available, such as Lipitor and other statins.

"This was a fantastic quarter. The new CEO's clearly getting things off with a bang," said Edward Jones analyst Judson Clark, adding, "We wouldn't expect that to repeat itself."

Clark said that's because this quarter had a one-time gain of $206 million, and stock buybacks reduced the number of outstanding shares by 16 percent. The lower share total, in return, increased earnings per share.

The $206 million payment came from Takeda Pharmaceutical Co. Ltd. The two companies, which have been collaborating since 2008 on an experimental drug called motesanib for a type of lung cancer, changed their agreement, giving Takeda all rights to develop and sell it.

Sales were led by Neulasta and Neupogen, which treat the decline of infection-fighting white blood cells caused by cancer and other disorders. They brought in a total of $1.35 billion, up 2 percent. Enbrel posted an 11 percent jump in sales, to $991 million.

Amgen's newest drugs, Prolia and Xgeva, a different dose of the same active ingredient that's for preventing fractures in cancerous bones, brought in $120 million and $179 million, respectively.

"There was top-line growth across all the major product lines, in particular for Enbrel," said Credit Suisse analyst Ravi Mehrotra. He added that much of Enbrel's growth came from yet another price increase and it will be harder for Amgen to keep raising the 14-year-old drug's price nearly every year.

During the quarter, Amgen bought back 17 million shares of stock for a total of $1.2 billion.

The company also raised its adjusted profit forecast for 2012 to $6.20 to $6.35, up from its spring forecast of $5.90 to $6.15 per share, and said it expects revenue of between $16.9 billion and $17.2 billion. Analysts had expected $6.17 per on revenue of $16.4 billion.

Amgen's shares rose $3.51, or 4.4 percent, to $82.80 after hours, on top of a 1.7 percent gain during regular trading.

Explore further: Qualcomm reports stronger results, forecast


Related Stories

Research In Motion's 1Q profit jumps 20 percent

June 24, 2010

(AP) -- BlackBerry maker Research In Motion Ltd. posted a 20 percent jump in net income for the most recent quarter, but the company's revenue and subscriber growth disappointed investors.

CenturyLink 3Q net income falls as expenses rise

November 2, 2011

(AP) -- Phone company CenturyLink Inc. says its third-quarter net income fell as rising operating expenses related to its April acquisition of larger phone company Qwest overshadowed increased revenue.

Qualcomm 3Q results beat Wall Street estimates

July 20, 2011

(AP) -- Wireless chip-maker Qualcomm Inc.'s results for the latest quarter beat Wall Street's expectations, and its projections for the current quarter are also above analysts' estimates.

Oracle fiscal 3Q net income up 78 pct

March 24, 2011

(AP) -- Database software maker Oracle Corp. said Thursday its net income rose 78 percent in the fiscal third quarter, helped by a rise in new software license sales and the benefit of three full months of revenue from Sun ...

Recommended for you

Old, meet new: Drones, high-tech camera revamp archaeology

November 24, 2017

Scanning an empty field that once housed a Shaker village in New Hampshire, Jesse Casana had come in search of the foundations of stone buildings, long-forgotten roadways and other remnants of this community dating to the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.